drugset / Trial / NCT00549549

Celebrex In Acute Gouty Arthritis Study

NCT00549549

Phase 3 Completed 402 enrolled Viatris Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a multicenter, double-blind, double-dummy, randomized, active-controlled study that will include an 8-day treatment period followed by a 1-week follow-up period in patients experiencing symptoms of an acute exacerbation of gouty arthritis.

Timeline

Start
2008-02
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 50 mg
Subject Celecoxib Other / unclassified 200 mg
Subject Celecoxib Other / unclassified 400 mg
Comparator Indomethacin Small molecule 50 mg

Indications